Sangeetha Balaji
Sangeetha Balaji has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Swaminathan Ramasubramanian
Department of Orthopaedics, Government Medical College, Omandurar Government Estate, Chennai, India
8 shared publications - Madhan Jeyaraman
Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai, India
7 shared publications - Naveen Jeyaraman
Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai, India
7 shared publications - Filippo Migliorini
Department of Trauma and Reconstructive Surgery, University Hospital of Halle, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany
5 shared publications - Bishnu Prasad Patro
Orthopaedics, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, Odisha, India
2 shared publications - Nicola Maffulli
Department of Trauma and Orthopaedic Surgery, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Springer Nature in Journal of Translational Medicine
Comprehensive review of myalgic encephalomyelitis/chronic fatigue syndrome
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, debilitating disease that is unexplained and is characterised by persistent unexplained fatigue, Post Exertional Malaise (PEM), cognitive impairment, unrefreshing sleep and multisystem impairment. Despite the high burden of symptoms and the worldwide prevalence, ME/CFS has been poorly understood, underdiagnosed and underfunded. This large-scale review summarises the available evidence regarding the epidemiology, diagnostic progress, main clinical characteristics, pathophysiological theories and therapeutic approaches for ME/CFS. Despite problems with diagnostic consistency, the lack of validated biomarkers, and historical linkage to psychiatric illness, the recognition of this condition has been delayed and has led to patient marginalisation. The review highlights PEM as a cardinal symptom and reviews the weaknesses in earlier diagnostic criteria, as well as current changes in treatment guidelines, including the formal withdrawal of Graded Exercise Therapy, which has evidence of harm. New pathophysiological evidence suggests mitochondrial dysfunction, immune dysregulation, autonomic imbalance, neuroinflammation, and alterations in gut microbiome. New diagnostic and therapeutic strategies, such as metabolomic and electrophysiological assays, mTOR inhibitors, and decentralised clinical trial designs, are being studied. This intersection with Long COVID offers a chance to rapidly advance studies of post-infectious chronic diseases. The paper also argues for stringent subtyping, uniform data collection, and ongoing patient participation in research as strategies to surmount challenges of heterogeneity. Finally, it underscores the critical need for fair funding of research, so biomarker discovery and development of disease-modifying treatments can be achieved. The care of people with ME/CFS is not only a clinical obligation, but also a public health one.
- 28 August 2026
- Published by Springer Nature in Journal of Translational Medicine
Open AccessComprehensive review of myalgic encephalomyelitis/chronic fatigue syndrome
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, debilitating disease that is unexplained and is characterised by persistent unexplained fatigue, Post Exertional Malaise (PEM), cognitive impairment, unrefreshing sleep and multisystem impairment. Despite the high burden of symptoms and the worldwide prevalence, ME/CFS has been poorly understood, underdiagnosed and underfunded. This large-scale review summarises the available evidence regarding the epidemiology, diagnostic progress, main clinical characteristics, pathophysiological theories and therapeutic approaches for ME/CFS. Despite problems with diagnostic consistency, the lack of validated biomarkers, and historical linkage to psychiatric illness, the recognition of this condition has been delayed and has led to patient marginalisation. The review highlights PEM as a cardinal symptom and reviews the weaknesses in earlier diagnostic criteria, as well as current changes in treatment guidelines, including the formal withdrawal of Graded Exercise Therapy, which has evidence of harm. New pathophysiological evidence suggests mitochondrial dysfunction, immune dysregulation, autonomic imbalance, neuroinflammation, and alterations in gut microbiome. New diagnostic and therapeutic strategies, such as metabolomic and electrophysiological assays, mTOR inhibitors, and decentralised clinical trial designs, are being studied. This intersection with Long COVID offers a chance to rapidly advance studies of post-infectious chronic diseases. The paper also argues for stringent subtyping, uniform data collection, and ongoing patient participation in research as strategies to surmount challenges of heterogeneity. Finally, it underscores the critical need for fair funding of research, so biomarker discovery and development of disease-modifying treatments can be achieved. The care of people with ME/CFS is not only a clinical obligation, but also a public health one.
- 25 August 2025
- Published by Elsevier in Journal of Clinical Orthopaedics and Trauma
- Vol. 70, 103184
Striking the balance: A deep dive into wellness and work-life harmony in orthopaedic education – A comprehensive review
- 25 August 2025
- Published by Elsevier in Journal of Clinical Orthopaedics and Trauma
- Vol. 70, 103184
Striking the balance: A deep dive into wellness and work-life harmony in orthopaedic education – A comprehensive review
- 12 July 2025
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 59 (8) , 1112-1122
Bio-Active Composite Therapy (BACT) in Regenerative Orthopaedics
Background Bio-Active Composite Therapy (BACT) represents a significant advancement in regenerative orthopaedics, integrating bioactive materials with biological systems to enhance bone and tissue regeneration. This comprehensive approach leverages materials such as hydroxyapatite, bioactive glasses, polymers, and metals to create scaffolds that mimic the extracellular matrix, facilitating cellular activities essential for tissue repair. Methods A systematic literature review was conducted using databases including PubMed, Scopus, Web of Science, and Google Scholar. Keywords such as “Bio-Active Composite Therapy,” “regenerative orthopaedics,” and “bioactive materials” were employed to identify relevant studies published between 2000 and 2024. Inclusion criteria focused on peer-reviewed articles, reviews, and clinical trials related to the development, application, and evaluation of BACT in bone and soft tissue regeneration. Data extraction emphasized bioactive material types, fabrication techniques, clinical applications, outcomes, and associated challenges. The findings were categorized thematically to synthesize current advancements and identify knowledge gaps. Results BACT utilizes a diverse range of bioactive materials, with hydroxyapatite and bioactive glasses being predominant due to their osteoconductive and osteoinductive properties. Advanced fabrication techniques, particularly additive manufacturing (e.g., 3D printing), enable the creation of scaffolds with precise geometries and tailored porosity, enhancing cellular adhesion and proliferation. Clinically, BACT has demonstrated efficacy in bone regeneration, cartilage repair, and ligament healing, although biocompatibility and immunotoxicity remain challenges, especially with certain metal oxides like TiO₂. Economic barriers and technical precision in scaffold application also pose significant limitations. Conclusion BACT holds transformative potential in regenerative orthopaedics by offering tailored, effective treatments for musculoskeletal disorders. Overcoming biocompatibility, safety, and accessibility challenges through interdisciplinary collaboration and technological innovation is essential for its widespread clinical adoption. Future research should focus on optimizing bioactive materials and fabrication methods, alongside rigorous clinical trials to validate long-term efficacy and safety. Graphical Abstract
- 12 July 2025
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 59 (8) , 1112-1122
Bio-Active Composite Therapy (BACT) in Regenerative Orthopaedics
Background Bio-Active Composite Therapy (BACT) represents a significant advancement in regenerative orthopaedics, integrating bioactive materials with biological systems to enhance bone and tissue regeneration. This comprehensive approach leverages materials such as hydroxyapatite, bioactive glasses, polymers, and metals to create scaffolds that mimic the extracellular matrix, facilitating cellular activities essential for tissue repair. Methods A systematic literature review was conducted using databases including PubMed, Scopus, Web of Science, and Google Scholar. Keywords such as “Bio-Active Composite Therapy,” “regenerative orthopaedics,” and “bioactive materials” were employed to identify relevant studies published between 2000 and 2024. Inclusion criteria focused on peer-reviewed articles, reviews, and clinical trials related to the development, application, and evaluation of BACT in bone and soft tissue regeneration. Data extraction emphasized bioactive material types, fabrication techniques, clinical applications, outcomes, and associated challenges. The findings were categorized thematically to synthesize current advancements and identify knowledge gaps. Results BACT utilizes a diverse range of bioactive materials, with hydroxyapatite and bioactive glasses being predominant due to their osteoconductive and osteoinductive properties. Advanced fabrication techniques, particularly additive manufacturing (e.g., 3D printing), enable the creation of scaffolds with precise geometries and tailored porosity, enhancing cellular adhesion and proliferation. Clinically, BACT has demonstrated efficacy in bone regeneration, cartilage repair, and ligament healing, although biocompatibility and immunotoxicity remain challenges, especially with certain metal oxides like TiO₂. Economic barriers and technical precision in scaffold application also pose significant limitations. Conclusion BACT holds transformative potential in regenerative orthopaedics by offering tailored, effective treatments for musculoskeletal disorders. Overcoming biocompatibility, safety, and accessibility challenges through interdisciplinary collaboration and technological innovation is essential for its widespread clinical adoption. Future research should focus on optimizing bioactive materials and fabrication methods, alongside rigorous clinical trials to validate long-term efficacy and safety. Graphical Abstract
- Open Access
- 15 June 2025
- Published by IP Innovative Publication Pvt Ltd in IP International Journal of Orthopaedic Rheumatology
- Vol. 11 (1) , 22-31
Diffuse idiopathic skeletal hyperostosis: A review of current literature
Diffuse idiopathic skeletal hyperostosis: A review of current literature - IJOR- Print ISSN No: - 2581-8112 Online ISSN No:- 2581-9151 Article DOI No:- 10.18231/j.ijor.2025.004, IP International Journal of Orthopaedic Rheumatology-IP Int J Orthop Rheumatol
- 15 June 2025
- Published by IP Innovative Publication Pvt Ltd in IP International Journal of Orthopaedic Rheumatology
- Vol. 11 (1) , 22-31
Open AccessDiffuse idiopathic skeletal hyperostosis: A review of current literature
Diffuse idiopathic skeletal hyperostosis: A review of current literature - IJOR- Print ISSN No: - 2581-8112 Online ISSN No:- 2581-9151 Article DOI No:- 10.18231/j.ijor.2025.004, IP International Journal of Orthopaedic Rheumatology-IP Int J Orthop Rheumatol
- Open Access
- 12 December 2024
- Published by MDPI AG in Medical Sciences
- Vol. 12 (4) , 72
Molecular Mimicry Between Gut Microbiome and Rheumatoid Arthritis: Current Concepts
Rheumatoid arthritis (RA) represents an autoimmune condition impacted by a combination of genetic and environmental factors, with the gut microbiome (GMB) being one of the influential environmental factors. Patients with RA display notable modifications in the composition of their GMB, characterised by decreased diversity and distinct bacterial alterations. The GMB, comprising an extensive array of approximately 35,000 bacterial species residing within the gastrointestinal tract, has garnered considerable attention as a pivotal contributor to both human health and the pathogenesis of diseases. This article provides an in-depth exploration of the intricate involvement of the GMB in the context of RA. The oral–GMB axis highlights the complex role of bacteria in RA pathogenesis by producing antibodies to citrullinated proteins (ACPAs) through molecular mimicry. Dysbiosis affects Tregs, cytokine levels, and RA disease activity, suggesting that regulating cytokines could be a strategy for managing inflammation in RA. The GMB also has significant implications for drug responses and toxicity, giving rise to the field of pharmacomicrobiomics. The composition of the microbiota can impact the efficacy and toxicity of drugs, while the microbiota’s metabolites can influence drug response. Recent research has identified specific bacteria, metabolites, and immune responses associated with RA, offering potential targets for personalised management. However, several challenges, including the variation in microbial composition, establishing causality, accounting for confounding factors, and translating findings into clinical practice, need to be addressed. Microbiome-targeted therapy is still in its early stages and requires further research and standardisation for effective implementation.
- 12 December 2024
- Published by MDPI AG in Medical Sciences
- Vol. 12 (4) , 72
Open AccessMolecular Mimicry Between Gut Microbiome and Rheumatoid Arthritis: Current Concepts
Rheumatoid arthritis (RA) represents an autoimmune condition impacted by a combination of genetic and environmental factors, with the gut microbiome (GMB) being one of the influential environmental factors. Patients with RA display notable modifications in the composition of their GMB, characterised by decreased diversity and distinct bacterial alterations. The GMB, comprising an extensive array of approximately 35,000 bacterial species residing within the gastrointestinal tract, has garnered considerable attention as a pivotal contributor to both human health and the pathogenesis of diseases. This article provides an in-depth exploration of the intricate involvement of the GMB in the context of RA. The oral–GMB axis highlights the complex role of bacteria in RA pathogenesis by producing antibodies to citrullinated proteins (ACPAs) through molecular mimicry. Dysbiosis affects Tregs, cytokine levels, and RA disease activity, suggesting that regulating cytokines could be a strategy for managing inflammation in RA. The GMB also has significant implications for drug responses and toxicity, giving rise to the field of pharmacomicrobiomics. The composition of the microbiota can impact the efficacy and toxicity of drugs, while the microbiota’s metabolites can influence drug response. Recent research has identified specific bacteria, metabolites, and immune responses associated with RA, offering potential targets for personalised management. However, several challenges, including the variation in microbial composition, establishing causality, accounting for confounding factors, and translating findings into clinical practice, need to be addressed. Microbiome-targeted therapy is still in its early stages and requires further research and standardisation for effective implementation.
- 24 August 2024
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 58 (10) , 1349-1361
Chondrogenic Potential of Umbilical Cord-Derived Mesenchymal Stromal Cells: Insights and Innovations
Background The advent of tissue engineering and regenerative medicine has introduced innovative approaches to treating degenerative and traumatic injuries, particularly in cartilage, a tissue with limited self-repair capabilities. Among the various stem cell sources, umbilical cord-derived mesenchymal stromal cells (UC-MSCs) have garnered significant interest due to their non-invasive collection, minimal ethical concerns, and robust regenerative potential, particularly in cartilage regeneration. Methods A comprehensive literature review was conducted using multiple databases, including PubMed, Scopus, Web of Science, and Google Scholar. Search terms focused on "umbilical cordderived mesenchymal stromal cells," "chondrogenesis," "cartilage regeneration," and related topics. Studies published in the past two decades were included, with selection criteria emphasizing methodological rigor and relevance to UC-MSC chondrogenesis. The review synthesizes findings from various sources to provide a thorough analysis of the potential of UC-MSCs in cartilage tissue engineering. Results UC-MSCs exhibit significant chondrogenic potential, supported by their ability to differentiate into chondrocytes under specific conditions. Recent advancements include the development of biomaterial scaffolds and the application of genetic engineering techniques, such as CRISPR/Cas9, to enhance chondrogenic differentiation. Despite these advancements, challenges remain in standardizing cell isolation techniques, scaling up production for clinical use, and ensuring the long-term functionality of regenerated cartilage. Conclusion UC-MSCs offer a promising solution for cartilage regeneration in the field of regenerative medicine. Ongoing research is focused on overcoming current challenges through the use of advanced technologies, including bioreactors and gene editing. Collaborative efforts among researchers, clinicians, and bioengineers are essential to translating the potential of UC-MSCs into effective clinical therapies, which could significantly advance tissue regeneration and therapeutic innovation. Graphical Abstract
- 24 August 2024
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 58 (10) , 1349-1361
Chondrogenic Potential of Umbilical Cord-Derived Mesenchymal Stromal Cells: Insights and Innovations
Background The advent of tissue engineering and regenerative medicine has introduced innovative approaches to treating degenerative and traumatic injuries, particularly in cartilage, a tissue with limited self-repair capabilities. Among the various stem cell sources, umbilical cord-derived mesenchymal stromal cells (UC-MSCs) have garnered significant interest due to their non-invasive collection, minimal ethical concerns, and robust regenerative potential, particularly in cartilage regeneration. Methods A comprehensive literature review was conducted using multiple databases, including PubMed, Scopus, Web of Science, and Google Scholar. Search terms focused on "umbilical cordderived mesenchymal stromal cells," "chondrogenesis," "cartilage regeneration," and related topics. Studies published in the past two decades were included, with selection criteria emphasizing methodological rigor and relevance to UC-MSC chondrogenesis. The review synthesizes findings from various sources to provide a thorough analysis of the potential of UC-MSCs in cartilage tissue engineering. Results UC-MSCs exhibit significant chondrogenic potential, supported by their ability to differentiate into chondrocytes under specific conditions. Recent advancements include the development of biomaterial scaffolds and the application of genetic engineering techniques, such as CRISPR/Cas9, to enhance chondrogenic differentiation. Despite these advancements, challenges remain in standardizing cell isolation techniques, scaling up production for clinical use, and ensuring the long-term functionality of regenerated cartilage. Conclusion UC-MSCs offer a promising solution for cartilage regeneration in the field of regenerative medicine. Ongoing research is focused on overcoming current challenges through the use of advanced technologies, including bioreactors and gene editing. Collaborative efforts among researchers, clinicians, and bioengineers are essential to translating the potential of UC-MSCs into effective clinical therapies, which could significantly advance tissue regeneration and therapeutic innovation. Graphical Abstract
- Open Access
- 14 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4794
Metamizole in the Management of Musculoskeletal Disorders: Current Concept Review
Metamizole, or dipyrone, has been used for decades as a non-narcotic analgesic, providing pain relief from musculoskeletal disorders and antipyretic and antispasmolytic properties. Despite being in use since the 1920s, its mechanism of action still needs to be discovered. Despite causing fewer adverse effects when compared to other analgesics, its harmful effects on the blood and lack of evidence regarding its teratogenicity make the usage of the drug questionable, which has led to it being removed from the drug market of various countries. This narrative review aims to provide a detailed insight into the mechanism of action and efficacy, comparing its effectiveness and safety with other classes of drugs and the safety profile of metamizole.
- 14 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4794
Open AccessMetamizole in the Management of Musculoskeletal Disorders: Current Concept Review
Metamizole, or dipyrone, has been used for decades as a non-narcotic analgesic, providing pain relief from musculoskeletal disorders and antipyretic and antispasmolytic properties. Despite being in use since the 1920s, its mechanism of action still needs to be discovered. Despite causing fewer adverse effects when compared to other analgesics, its harmful effects on the blood and lack of evidence regarding its teratogenicity make the usage of the drug questionable, which has led to it being removed from the drug market of various countries. This narrative review aims to provide a detailed insight into the mechanism of action and efficacy, comparing its effectiveness and safety with other classes of drugs and the safety profile of metamizole.
- Open Access
- 31 July 2024
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-13
Ozone therapy in musculoskeletal medicine: a comprehensive review
Musculoskeletal disorders encompass a wide range of conditions that impact the bones, joints, muscles, and connective tissues within the body. Despite the ongoing debate on toxicity and administration, ozone demonstrated promise in managing several musculoskeletal disorders, modulating pain and inflammation. A literature search was conducted. The research design, methods, findings, and conclusions of the studies were then examined to evaluate the physiological effects, clinical application, controversies, and safety of the application of ozone in musculoskeletal medicine. Ozone application demonstrates considerable therapeutic applications in the management of musculoskeletal disorders, including fractures, osteoarthritis, and chronic pain syndromes. Despite these advantages, studies have raised concerns regarding its potential toxicity and emphasized the importance of adhering to stringent administration protocols to ensure safety. Additionally, heterogeneities in patient reactions and hazards from oxidizing agents were observed. Given its anti-inflammatory and analgesic qualities, ozone therapy holds potential in the management of several musculoskeletal disorders. Additional high-quality research with long follow-up is required to refine indications, efficacy and safety profile. Finally, for wider clinical acceptability and utilization, the development of international recommendations is essential.
- 31 July 2024
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-13
Open AccessOzone therapy in musculoskeletal medicine: a comprehensive review
Musculoskeletal disorders encompass a wide range of conditions that impact the bones, joints, muscles, and connective tissues within the body. Despite the ongoing debate on toxicity and administration, ozone demonstrated promise in managing several musculoskeletal disorders, modulating pain and inflammation. A literature search was conducted. The research design, methods, findings, and conclusions of the studies were then examined to evaluate the physiological effects, clinical application, controversies, and safety of the application of ozone in musculoskeletal medicine. Ozone application demonstrates considerable therapeutic applications in the management of musculoskeletal disorders, including fractures, osteoarthritis, and chronic pain syndromes. Despite these advantages, studies have raised concerns regarding its potential toxicity and emphasized the importance of adhering to stringent administration protocols to ensure safety. Additionally, heterogeneities in patient reactions and hazards from oxidizing agents were observed. Given its anti-inflammatory and analgesic qualities, ozone therapy holds potential in the management of several musculoskeletal disorders. Additional high-quality research with long follow-up is required to refine indications, efficacy and safety profile. Finally, for wider clinical acceptability and utilization, the development of international recommendations is essential.
- 17 April 2024
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 34 (5) , 2245-2254
Whole-body cryotherapy in orthopaedics: current concepts
The use of whole-body cryotherapy (WBC) for musculoskeletal ailments is growing. WBC, involving brief exposure to extremely low temperatures, is increasingly used for its analgesic, anti-inflammatory, and antioxidant effects. The paper examines the physiological impacts of WBC on cardiovascular, musculoskeletal, hematologic, hormonal, and metabolic systems. Specific orthopaedic applications discussed include its role in the management of fractures, osteoarthritis, osteonecrosis of the femoral head, osteomyelitis, adhesive capsulitis, tendinopathies, rheumatic pathologies, chronic pain syndromes, and fibromyalgia. The study also highlights the benefits and drawbacks of WBC, including its potential to improve athletic performance, recovery, mood, and well-being, while noting risks like frostbite and impaired muscle strength. Clinical evidence from various studies is evaluated, revealing a spectrum of outcomes. For instance, WBC shows promise in enhancing bone health in athletes and providing relief in osteoarthritis and fibromyalgia patients. However, evidence for its efficacy in conditions like chronic pain syndromes and osteomyelitis is less robust. The paper underscores the need for further research to establish standardised protocols and understand long-term effects. While WBC offers significant benefits in orthopaedics, understanding its limitations and potential risks is crucial for its safe and effective clinical application.
- 17 April 2024
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 34 (5) , 2245-2254
Whole-body cryotherapy in orthopaedics: current concepts
The use of whole-body cryotherapy (WBC) for musculoskeletal ailments is growing. WBC, involving brief exposure to extremely low temperatures, is increasingly used for its analgesic, anti-inflammatory, and antioxidant effects. The paper examines the physiological impacts of WBC on cardiovascular, musculoskeletal, hematologic, hormonal, and metabolic systems. Specific orthopaedic applications discussed include its role in the management of fractures, osteoarthritis, osteonecrosis of the femoral head, osteomyelitis, adhesive capsulitis, tendinopathies, rheumatic pathologies, chronic pain syndromes, and fibromyalgia. The study also highlights the benefits and drawbacks of WBC, including its potential to improve athletic performance, recovery, mood, and well-being, while noting risks like frostbite and impaired muscle strength. Clinical evidence from various studies is evaluated, revealing a spectrum of outcomes. For instance, WBC shows promise in enhancing bone health in athletes and providing relief in osteoarthritis and fibromyalgia patients. However, evidence for its efficacy in conditions like chronic pain syndromes and osteomyelitis is less robust. The paper underscores the need for further research to establish standardised protocols and understand long-term effects. While WBC offers significant benefits in orthopaedics, understanding its limitations and potential risks is crucial for its safe and effective clinical application.